Asset Details
Do you wish to reserve the book?
Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
Do you wish to request the book?
Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
2013
Overview
Introduction
The discovery of activating
KIT
and
PDGFRα
mutations in gastrointestinal stromal tumors (GISTs) represented a milestone as it allowed clinicians to use tyrosine kinase inhibitors, like imatinib, to treat this sarcoma. Although surgery remains the only potentially curative treatment, patients who undergo complete resection may still experience local recurrence or distant metastases. Therapeutic strategies that combine surgical resection and adjuvant imatinib may represent the best treatment to maximize patient outcomes. In addition to the use of imatinib in the adjuvant and metastatic settings, neoadjuvant imatinib, employed as a cytoreductive therapy, can decrease tumor volume, increase the probability of complete resection, and may reduce surgery-related morbidities. Thus, selected patients with metastatic disease may be treated with a combination of preoperative imatinib and metastasectomy. However, it is critical that patients with GIST be evaluated by a multidisciplinary team to coordinate surgery and targeted therapy in order to maximize clinical outcomes.
Discussion
Following a systematic literature review, we describe the presentation, diagnosis, and treatment of GIST, with a discussion of the risk assessment for imatinib therapy. The application of surgical options, combined with adjuvant/neoadjuvant or perioperative imatinib, and their potential impact on survival for patients with primary, recurrent, or metastatic GIST are discussed.
Publisher
Springer US,Springer Nature B.V
Subject
Antineoplastic Agents - therapeutic use
/ Benzamides - therapeutic use
/ Gastrointestinal Neoplasms - diagnosis
/ Gastrointestinal Neoplasms - pathology
/ Gastrointestinal Neoplasms - therapy
/ Gastrointestinal Stromal Tumors - diagnosis
/ Gastrointestinal Stromal Tumors - secondary
/ Gastrointestinal Stromal Tumors - therapy
/ Humans
/ Kinases
/ Medicine
/ Mutation
/ Neoplasm Recurrence, Local - surgery
/ Oncology
/ Patients
/ Piperazines - therapeutic use
/ Pyrimidines - therapeutic use
/ Review
/ Surgery
/ Tumors
